

London, 2<sup>nd</sup> September 2024

Dear Dr Fruhwirth,

I am delighted to inform you that, in recognition of your expertise and anticipated contributions to Prof Simon Ameer-Beg's recently awarded Wellcome Technology Development grant (Grant reference: 311428/Z/24/Z), you will be accorded the status of co-investigator. This is in full recognition of your involvement in the development of the project (attributed 15% credit on Worktribe) and in the expectation that, through this collaboration, you will have significant involvement in the expansion phase of the project to help co-create the translational potential of the novel set of developments funded through this project.

On behalf of the Comprehensive Cancer Centre and the School of Cancer and Pharmaceutical Sciences, I am delighted to express my full support for the innovative proposal led by Professor Simon Ameer-Beg and his esteemed colleagues. This project aims to revolutionise the understanding of cellular and tissue function through the development of advanced microscopical tools, focusing on spatial-temporal regulation of cell-signalling and metabolism through sensing with both autofluorescence of metabolites and fluorescent biosensors. The programme described within the case for support transcends traditional field boundaries, developing imaging methods across the molecular, cellular, and tissue scales. Enabling them to probe the spatio-temporal responses of mitochondria, observe cell reactions to perturbations in real-time, and compare metabolic profiles within different cell-types and ultimately within tissues *in vivo*. By correlating these observations with complementary technologies (such as proteomics and transcriptomics), the project will deepen our understanding of how metabolic and homeostatic signalling at the nanoscale propagates across distances within mitochondrion, single cells and, across organoids and tissues

As a Co-Investigator, your primary role will involve the design and development of advanced sensors crucial to the success of this programme. Additionally, you will be responsible for co-supervision of a Post-Doctoral Researcher (PDR) who will be tasked with delivering the biological objectives of the project. Your collaboration with other biological partners and developing pre-clinical and translational objectives will be integral to ensuring that the project achieves its potential. Submission of a project extension to a programme scale up phase in October 2025 will seek to fully recognise your contribution to the programme assuming Wellcome Trust allow additional Co-investigators to be acknowledged.

School of Cancer &  
Pharmaceutical Sciences

Comprehensive Cancer Centre

Faculty of Life & Sciences & Medicine  
King's College London

Anita Grigoriadis, PhD  
Professor of Molecular & Digital Pathology

Head of Comprehensive Cancer Centre  
Joint Head of School of Cancer &  
Pharmaceutical Sciences (interim)

CRUK City of London Centre, Training Lead

Innovation Hub  
Cancer Centre at Guy's Hospital  
London SE1 9RT, UK  
Tel: + 44 (0) 20 7188 3260  
Email: [anita.grigoriadis@kcl.ac.uk](mailto:anita.grigoriadis@kcl.ac.uk)  
[Ea-headsofschoolcps@kcl.ac.uk](mailto:Ea-headsofschoolcps@kcl.ac.uk)



We are confident that your contributions will be invaluable to the success of this programme, and we look forward to participating in your success.

Please consider this letter as official recognition of school support for Co-Investigator status to be applied with respect to promotions and other internal applications.

Please do not hesitate to contact me if there are any further queries.

Yours sincerely,

A handwritten signature in black ink, reading 'Anita Grigoriadis'.

Anita Grigoriadis

Professor of Molecular and Digital Pathology

Head of Comprehensive Cancer Centre (interim)

joint Head of School of Cancer and Pharmaceutical Sciences (interim)